全基因组 CRISPR 筛选鉴定 LAPTM5 驱动肝癌对仑伐替尼耐药。
Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
机构信息
Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
出版信息
Autophagy. 2023 Apr;19(4):1184-1198. doi: 10.1080/15548627.2022.2117893. Epub 2022 Sep 7.
Abstract
cld-CASP3: cleaved caspase 3; cld-PARP: cleaved PARP; DTP: drug tolerant persister; GO: Gene Ontology; GTEx: The Genotype-Tissue Expression; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; IC50: half maximal inhibitory concentration value; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAPTM5: lysosomal protein transmembrane 5; NT: non-targeting; PDC: patient-derived primary cell lines; PDO: patient-derived primary organoid; TCGA: The Cancer Genome Atlas.
摘要
cld-CASP3：裂解的半胱氨酸天冬氨酸蛋白酶 3；cld-PARP：裂解的多聚（ADP-核糖）聚合酶；DTP：耐药持久细胞；GO：基因本体论；GTEx：基因型-组织表达；HCC：肝细胞癌；HCQ：羟氯喹；IC50：半最大抑制浓度值；KEGG：京都基因与基因组百科全书；LAPTM5：溶酶体蛋白跨膜 5；NT：非靶向；PDC：患者来源的原代细胞系；PDO：患者来源的原代类器官；TCGA：癌症基因组图谱。
相似文献
1
Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
Autophagy. 2023 Apr;19(4):1184-1198. doi: 10.1080/15548627.2022.2117893. Epub 2022 Sep 7.
2
Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Biochem Biophys Res Commun. 2020 Jun 11;526(4):1170-1176. doi: 10.1016/j.bbrc.2020.04.040. Epub 2020 Apr 18.
3
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma modulation of lysosomal functions.
Autophagy. 2022 Mar;18(3):678-694. doi: 10.1080/15548627.2021.1988357. Epub 2021 Nov 5.
4
Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Lab Invest. 2018 Jun;98(6):734-744. doi: 10.1038/s41374-018-0027-6. Epub 2018 Feb 21.
5
Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
Carcinogenesis. 2020 May 14;41(3):345-357. doi: 10.1093/carcin/bgz104.
6
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.
Protein Cell. 2022 Nov;13(11):825-841. doi: 10.1007/s13238-022-00906-6. Epub 2022 Feb 26.
7
Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively.
J Cancer Res Clin Oncol. 2020 Jun;146(6):1509-1521. doi: 10.1007/s00432-020-03207-9. Epub 2020 Apr 7.
8
Strategies for HCC target discovery.
Aging (Albany NY). 2017 Apr;9(4):1088-1089. doi: 10.18632/aging.101233.
9
Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Int J Biol Sci. 2022 Jul 4;18(11):4357-4371. doi: 10.7150/ijbs.69969. eCollection 2022.
10
CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Gastroenterology. 2017 Dec;153(6):1662-1673.e10. doi: 10.1053/j.gastro.2017.09.008. Epub 2017 Sep 18.
引用本文的文献
1
WDFY4 Promotes the Progression of Atherosclerosis by Regulating Ferroptosis Mediated by the LAPTM5/CDC42/mTOR/4EBP1/SLC7A11 Pathway.
J Cell Mol Med. 2025 Aug;29(15):e70729. doi: 10.1111/jcmm.70729.
2
Different inhibitory effect of a neuropilin-1 monoclonal antibody on different types of hepatocellular carcinoma.
Discov Oncol. 2025 Jul 29;16(1):1437. doi: 10.1007/s12672-025-03149-z.
3
Efficacy of Lenvatinib Versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Asian Pac J Cancer Prev. 2025 Jun 1;26(6):1943-1952. doi: 10.31557/APJCP.2025.26.6.1943.
4
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy.
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01308-4.
5
Biomarker identification associated with M2 tumor-associated macrophage infiltration in glioblastoma.
Front Neurol. 2025 May 14;16:1545608. doi: 10.3389/fneur.2025.1545608. eCollection 2025.
6
Transcriptomics of Various Diseases Reveals the Core Role of Immune System Pathways in Retinal Damage Repair and Nerve Regeneration.
Mol Neurobiol. 2025 Apr 17. doi: 10.1007/s12035-025-04929-y.
7
ARL8B regulates lysosomal function and predicts poor prognosis in hepatocellular carcinoma.
Sci Rep. 2025 Apr 10;15(1):12278. doi: 10.1038/s41598-025-97616-w.
8
Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine.
Front Pharmacol. 2025 Mar 25;16:1563198. doi: 10.3389/fphar.2025.1563198. eCollection 2025.
9
Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma.
Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03371-7.
10
Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular Carcinoma.
Cell Mol Gastroenterol Hepatol. 2025;19(7):101502. doi: 10.1016/j.jcmgh.2025.101502. Epub 2025 Mar 20.
本文引用的文献
1
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Cancer Res. 2022 Feb 15;82(4):586-598. doi: 10.1158/0008-5472.CAN-21-1443.
2
Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance.
Cell Death Discov. 2021 Nov 18;7(1):359. doi: 10.1038/s41420-021-00747-y.
3
EGFR activation limits the response of liver cancer to lenvatinib.
Nature. 2021 Jul;595(7869):730-734. doi: 10.1038/s41586-021-03741-7. Epub 2021 Jul 21.
4
IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation.
Nat Commun. 2021 Jun 15;12(1):3651. doi: 10.1038/s41467-021-23923-1.
5
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Hepatology. 2021 Nov;74(5):2544-2560. doi: 10.1002/hep.31921. Epub 2021 Aug 25.
6
ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
J Hepatol. 2021 Apr;74(4):893-906. doi: 10.1016/j.jhep.2020.11.008. Epub 2020 Nov 13.
7
HGF protected against diabetic nephropathy via autophagy-lysosome pathway in podocyte by modulating PI3K/Akt-GSK3β-TFEB axis.
Cell Signal. 2020 Nov;75:109744. doi: 10.1016/j.cellsig.2020.109744. Epub 2020 Aug 19.
8
Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Med Oncol. 2020 Mar 12;37(4):24. doi: 10.1007/s12032-020-01350-4.
9
mRECIST for HCC: Performance and novel refinements.
J Hepatol. 2020 Feb;72(2):288-306. doi: 10.1016/j.jhep.2019.09.026.
10
miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Gut. 2020 Jul;69(7):1309-1321. doi: 10.1136/gutjnl-2019-318830. Epub 2019 Nov 14.
Zotero 插件